Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Trends in Cell Biology|December 13, 2005
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signalingJacqueline M Mason, Debra J Morrison, M Albert Basson, et al.
The Journal of Biological Chemistry|March 5, 2002
Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinasesRizwan Haq, Adrienne Halupa, Bryan K Beattie, et al.
Molecular Biology of the Cell|March 9, 2004
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loopJacqueline M Mason, Debra J Morrison, Bhramdeo Bassit, et al.
Molecular Cell|November 23, 2015
Targeting Mitosis in Cancer: Emerging StrategiesCarmen Dominguez-Brauer, Kelsie L Thu, Jacqueline M Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2017
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancerJacqueline M Mason, Xin Wei, Graham C Fletcher, et al.
Neoplasia (New York, N.Y.)|January 31, 2008
A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16Marianne K-H Kim, Jacqueline M Mason, Chi-Ming Li, et al.
Cancer Cell|July 22, 2014
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agentJacqueline M Mason, Dan Chi-Chia Lin, Xin Wei, et al.
The American Journal of Pathology|December 8, 2004
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumorsChi-Ming Li, Connie E Kim, Adam A Margolin, et al.
Leukemia|December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasmsTracy Murphy, Jacqueline M Mason, Brian Leber, et al.
Bioorganic & Medicinal Chemistry Letters|September 6, 2016
Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacySze-Wan Li, Yong Liu, Peter B Sampson, et al.
Pageof 2